Clinical Trial Update: A Phase 1/2 Study of AEB1102 in Patients With Arginase I Deficiency [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial of AEB1102 in Arginase I deficiency/hyperargininemia completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arginase Deficiency
• Hyperargininemia

Drugs mentioned

• AEB1102

Snippet

Sponsor: Aeglea Biotherapeutics | Conditions: Arginase I Deficiency, Hyperargininemia | Phase 1, Phase 2 | Status: COMPLETED